New anthyarrhythmic drugs for atrial fibrillation

References

• 1 Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33, 2719–2747 (2012).
  MedlineGoogle Scholar
• 2 Naccarelli GV, Wolbrette DL, Samii S et al. Vernakalant—a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin. Investig. Drugs 17, 805–810 (2008).
  Medline CASGoogle Scholar
• 3 Eldstrom J, Wang Z, Xu H et al. The molecular basis of high-affinity binding of the antiarrhythmic compound Vernakalant ( RSD1235) to Kv1. 5 channels. Mol. Pharmacol. 72(6), 1522–1534 (2007).
  Medline CASGoogle Scholar
• 4 Tian D, Frishman WH. A new drug to treat patients with acute onset atrial fibrillation. Cardiol. Rev. 19(1), 41–44 (2011).
  MedlineGoogle Scholar
• 5 Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs 16, 519–532 (2007).
  Medline CASGoogle Scholar
• 6 Mao ZL, Wheeler JJ, Clohs L et al. Pharmacokinetics of novel atrialselective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J. Clin. Pharmacol. 49, 17–29 (2009).
  Medline CASGoogle Scholar
• 7 Cheng JWM, Rybak I. Pharmacotherapy options in atrial fibrillation: focus on vernakalant. Clin. Med. Ther. 1, 215–230 (2009).
  CASGoogle Scholar
• 8 Roy D, Rowe BH, Stiell IG et al. CRAFT investigators. A randomized controlled trial of RSD 1235, a novel antiarrythmic agent in treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44(12), 2355–2361 (2004).
  Medline CASGoogle Scholar
• 9 Cardiome Pharma Corp. Vernakalant. www.cardiome.com
  Google Scholar
• 10 Roy D, Pratt CM, Torp-Pedersen C et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a Phase 3, randomized, placebo-controlled trial. Circulation 117(12), 1518–1525 (2008).
  Medline CASGoogle Scholar
• 11 Pratt CM, Roy D, Torp-Pederson C et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am. J. Cardiol. 106, 1277–1283 (2010).
  Medline CASGoogle Scholar
• 12 Kowey PR, Dorian P, Mitchell LB et al. Vernakalant Hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circulation 2, 652–659 (2009).
  MedlineGoogle Scholar
• 13 Camm AJ, Capucci A, Hohnloser SH et al. AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J. Am. Coll. Cardiol. 57(3), 313–321 (2011).
  MedlineGoogle Scholar
• 14 Camm AJ, Toft E, Torp-Pedersen C et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace 14, 804–809 (2012).
  MedlineGoogle Scholar
• 15 Stiell IG, Roos JS, Kavanagh KM et al. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am. Heart J. 159, 1095–1101 (2010).
  Medline CASGoogle Scholar
• 16 Schweizer P, Becker R, Katus H et al. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des. Dev. Ther. 27–39 (2011).
  MedlineGoogle Scholar
• 17 Dierk T, Kathofer S, Zhang W et al. Acute effects of dronedarone on both components of the cardiac delayed rectifier Kþ current, HERG and KvLQT1/minK potassium channels. Br. J. Pharmacol. 140, 996–1002 (2003).
  MedlineGoogle Scholar
• 18 Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (sr33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 100, 2276–2281 (1999).
  Medline CASGoogle Scholar
• 19 Patel C, Yan GX, Kowey PR. Dronedarone. Circulation 120, 636–644 (2009).
  Medline CASGoogle Scholar
• 20 Touboul P, Brugada J, Capucci A et al. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur. Heart J. 24, 1481–1487 (2003).
  Medline CASGoogle Scholar
• 21 Singh Bramah N, Connolly SJ, for the EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357(10), 987–999 (2007).
  Medline CASGoogle Scholar
• 22 Køber L, Torp-Pedersen C, McMurray JJV et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358(25), 2678–2687 (2008).
  MedlineGoogle Scholar
• 23 Hohnloser SH, Crijns HJGM, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668–678 (2009).
  Medline CASGoogle Scholar
• 24 Connolly SJ, Crijns HJGM, Torp-Pedersen C et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 120, 1174–1180 (2009).
  Medline CASGoogle Scholar
• 25 Hohnloser SH, Crijns HJGM, van Eickels M et al. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur. Heart J. 31, 1717–1721 (2010).
  Medline CASGoogle Scholar
• 26 Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Petersen C. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation: from the ATHENA trial. Am. J. Cardiol. 107(7), 1019–1022 (2011).
  Medline CASGoogle Scholar
• 27 Davy JM, Herold M, Hoglund C et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am. Heart J. 156, 527e1–9 (2008).
  Google Scholar
• 28 Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med. 365, 2268–2276 (2011).
  Medline CASGoogle Scholar
• 29 Le Heuzey JY, De Ferrari GM, Radzik D et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol. 21(16), 597–605 (2010).
  MedlineGoogle Scholar
• 30 Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline) 2011 writing group members. JACC 57, 223–242 (2011).
  MedlineGoogle Scholar
• 31 Burashnikov A, Di Diego JM, Zygmunt AC et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116, 1449–1457 (2007).
  Medline CASGoogle Scholar
• 32 Burashnikov A, Sicouri S, Di Diego JM et al. Synergistic effect of the combination of dronedarone and ranolazine to suppress atrial fibrillation. J. Am. Coll. Cardiol. 56, 1216–1224 (2010).
  Medline CASGoogle Scholar
• 33 Wilson SR, Scirica BM, Braunwald E et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN–TIMI (metabolic efficiency with ranolazine for less ischemia in non–ST-segment elevation acute coronary syndromes) 36 trial. J. Am. Coll. Cardiol. 4, 1510–1516 (2009).
  Google Scholar
• 34 Antzelevitch C, Burashnikov A, Sicouri S. Electrophysiological basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 8, 1281–1290 (2011).
  MedlineGoogle Scholar
• 35 Murdock DK, Kersten M, Kaliebe J et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible “pill in the pocket” approach to atrial fibrillation. Indian Pacing Electrophysiol. J. 9, 260–267 (2009).
  MedlineGoogle Scholar
• 36 Heijman J, Heusch G, Dobrev D. Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin. Med. Insights Cardiol. 7, 127–140 (2013).
  MedlineGoogle Scholar